Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Cash from Investing Activities: 2018-2024

Historic Cash from Investing Activities for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Dec 2024 value amounting to -$648,000.

  • Arcturus Therapeutics Holdings' Cash from Investing Activities fell 126.25% to -$181,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$726,000, marking a year-over-year increase of 52.33%. This contributed to the annual value of -$648,000 for FY2024, which is 77.66% up from last year.
  • As of FY2024, Arcturus Therapeutics Holdings' Cash from Investing Activities stood at -$648,000, which was up 77.66% from -$2.9 million recorded in FY2023.
  • Arcturus Therapeutics Holdings' Cash from Investing Activities' 5-year high stood at -$648,000 during FY2024, with a 5-year trough of -$7.7 million in FY2022.
  • Moreover, its 3-year median value for Cash from Investing Activities was -$2.9 million (2023), whereas its average is -$3.8 million.
  • In the last 5 years, Arcturus Therapeutics Holdings' Cash from Investing Activities slumped by 126.83% in 2022 and then spiked by 77.66% in 2024.
  • Arcturus Therapeutics Holdings' Cash from Investing Activities (Yearly) stood at -$1.7 million in 2020, then tumbled by 95.52% to -$3.4 million in 2021, then crashed by 126.83% to -$7.7 million in 2022, then skyrocketed by 62.45% to -$2.9 million in 2023, then soared by 77.66% to -$648,000 in 2024.